MICHAEL WEINER, M.D.

Corporate Board Profile

Tech Score: 0/100

SIGA TECHNOLOGIES INC

Filing Date	Source Excerpt
2001-07-31	Michael Weiner, M.D. has served as a Director of Siga since April 19, 2001. Dr. Weiner has been a Professor of Pediatrics at Columbia University College of Physicians and Surgeons since 1996. Dr. Weiner is also the Director of Pediatric Oncology at New York Presbyterian Hospital. Dr. Weiner was formerly a Director of Nexell Therapeutics, Inc. (f/k/a VimRx) from March 1996 to February 1999. Dr. Weiner is a 1972 graduate of the New York State Health Sciences Center at Syracuse, and he was a post graduate student at New York University and Johns Hopkins. Since June 29, 2001, Siga's audit committee has been composed of Drs. Mehmet Oz and Michael Weiner, neither of whom is an employee of Siga. Through its written charter, a copy of which is attached as Appendix 1 hereto, the audit committee has been delegated the responsibility of reviewing with the independent auditors the plans and results of the audit engagement, reviewing the adequacy, scope and results of the internal accounting controls and procedures, reviewing the degree of independence of the auditors, reviewing the auditor's fees and recommending the engagement of the auditors to the full Board of Directors. Since June 29, 2001, Siga's compensation committee has been composed of Drs. Mehmet Oz and Michael Weiner, neither of whom is an employee of Siga. The compensation committee administers Siga's stock option plan and other corporate benefits programs. The compensation committee also reviews and approves bonuses, stock option grants, compensation, philosophy and current competitive status, and executive officer compensation. During fiscal year 2000, no fees were paid to directors, and no directors were reimbursed for expenses incurred. Subject to the approval of the amendment and restatement of Siga's Amended 1996 Incentive and Non-Qualified Stock Option Plan (the "Option Plan") by our stockholders (Proposal 3 to be voted upon at the meeting to which this Proxy Statement relates), Siga has granted options ("Contingent Options") to purchase shares of Siga common stock to its directors under that plan. The number of shares for which each director has been granted Contingent Options is set forth in parentheses after his name: Michael Weiner (100,000). The exercise price for each Contingent Option will be $2.50, the fair market value at the date of grant, and all Contingent Options will be immediately exercisable upon approval of the amendment and restatement of the Option Plan.
2002-11-07	Michael Weiner, M.D. has served as a Director of SIGA since April 19, 2001. Dr. Weiner has been a Professor of Pediatrics at Columbia University College of Physicians and Surgeons since 1996. Dr. Weiner is also the Director of Pediatric Oncology at New York Presbyterian Hospital. Dr. Weiner was formerly a Director of Nexell Therapeutics, Inc. (f/k/a VimRx) from March 1996 to February 1999.

Filing Date

Source Excerpt

2001-07-31

Michael Weiner, M.D. has served as a Director of Siga since April 19, 2001. Dr. Weiner has been a Professor of Pediatrics at Columbia University College of Physicians and Surgeons since 1996. Dr. Weiner is also the Director of Pediatric Oncology at New York Presbyterian Hospital. Dr. Weiner was formerly a Director of Nexell Therapeutics, Inc. (f/k/a VimRx) from March 1996 to February 1999. Dr. Weiner is a 1972 graduate of the New York State Health Sciences Center at Syracuse, and he was a post graduate student at New York University and Johns Hopkins. Since June 29, 2001, Siga's audit committee has been composed of Drs. Mehmet Oz and Michael Weiner, neither of whom is an employee of Siga. Through its written charter, a copy of which is attached as Appendix 1 hereto, the audit committee has been delegated the responsibility of reviewing with the independent auditors the plans and results of the audit engagement, reviewing the adequacy, scope and results of the internal accounting controls and procedures, reviewing the degree of independence of the auditors, reviewing the auditor's fees and recommending the engagement of the auditors to the full Board of Directors. Since June 29, 2001, Siga's compensation committee has been composed of Drs. Mehmet Oz and Michael Weiner, neither of whom is an employee of Siga. The compensation committee administers Siga's stock option plan and other corporate benefits programs. The compensation committee also reviews and approves bonuses, stock option grants, compensation, philosophy and current competitive status, and executive officer compensation. During fiscal year 2000, no fees were paid to directors, and no directors were reimbursed for expenses incurred. Subject to the approval of the amendment and restatement of Siga's Amended 1996 Incentive and Non-Qualified Stock Option Plan (the "Option Plan") by our stockholders (Proposal 3 to be voted upon at the meeting to which this Proxy Statement relates), Siga has granted options ("Contingent Options") to purchase shares of Siga common stock to its directors under that plan. The number of shares for which each director has been granted Contingent Options is set forth in parentheses after his name: Michael Weiner (100,000). The exercise price for each Contingent Option will be $2.50, the fair market value at the date of grant, and all Contingent Options will be immediately exercisable upon approval of the amendment and restatement of the Option Plan.

2002-11-07

Michael Weiner, M.D. has served as a Director of SIGA since April 19, 2001. Dr. Weiner has been a Professor of Pediatrics at Columbia University College of Physicians and Surgeons since 1996. Dr. Weiner is also the Director of Pediatric Oncology at New York Presbyterian Hospital. Dr. Weiner was formerly a Director of Nexell Therapeutics, Inc. (f/k/a VimRx) from March 1996 to February 1999.

Data sourced from SEC filings. Last updated: 2026-02-08